Trial NCT04866017

View at ClinicalTrials.gov 
Org. Study IDs: BGB-A317-A1217-301
Secondary IDs: 2020-004656-14 AdvanTIG-301

Last trial update was posted on 2024-01-18

MeSH Interventions

Durvalumab Tislelizumab

MeSH Conditions

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Other Conditions

Non Small Cell Lung Cancer

Stopping Reasons

This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the ociperlimab program.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID